# OnCo record stage-iii-unresectable-nsclc (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/stage-iii-unresectable-nsclc/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "stage-iii-unresectable-nsclc" ;
  schema:name "Unresectable stage III non-small-cell lung cancer"@en ;
  schema:alternateName "Locally advanced non-small-cell lung cancer"@en, "Inoperable stage III NSCLC"@en, "Stage IIIB and IIIC NSCLC"@en ;
  schema:description "Stage III lung cancer that cannot be removed is treated with chemotherapy and radiotherapy together, aiming at cure. A year of the immunotherapy antibody durvalumab afterwards raised five-year survival from a third to over 40 percent, and for EGFR-mutated tumours osimertinib after chemoradiation holds the disease for years."@en ;
  schema:url <https://onco.cc/cancers/stage-iii-unresectable-nsclc/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Chemoradiotherapy> ;
  schema:citation <https://en.wikipedia.org/wiki/Chemoradiotherapy>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450> ;
  onco:tag "subtype-page", "lung" ;
  onco:technologies <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/pet-ct/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/platinum/>, <https://onco.cc/technologies/hypofractionated-radiotherapy/> ;
  onco:targets <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/egfr/> ;
  onco:drugs <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/vinorelbine/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/merck/> ;
  onco:institutions <https://onco.cc/institutions/nrg-oncology/> ;
  onco:pathways <https://onco.cc/pathways/pd1-checkpoint/> ;
  onco:terms <https://onco.cc/terms/chemoradiation/>, <https://onco.cc/terms/consolidation-therapy/>, <https://onco.cc/terms/radiation-pneumonitis/>, <https://onco.cc/terms/ild/>, <https://onco.cc/terms/tnm-staging/>, <https://onco.cc/terms/cancer-stage/>, <https://onco.cc/terms/mediastinum/> ;
  onco:trials <https://onco.cc/trials/pacific/>, <https://onco.cc/trials/laura/>, <https://onco.cc/trials/nct04380636/> ;
  onco:people <https://onco.cc/people/scott-antonia/>, <https://onco.cc/people/david-planchard/>, <https://onco.cc/people/wu-yi-long/>, <https://onco.cc/people/suresh-ramalingam/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-pacific-nejm-2017/> ;
  onco:pipeline <https://onco.cc/trials/nct04380636/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/intensity-modulated-proton-therapy/>, <https://onco.cc/trials/laura/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/technologies/mrd-testing/> ;
  onco:standardOfCare <https://onco.cc/trials/pacific/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/terms/chemoradiation/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/terms/consolidation-therapy/>, <https://onco.cc/trials/laura/>, <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/terms/chemoradiation/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/hypofractionated-radiotherapy/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/terms/radiation-pneumonitis/>, <https://onco.cc/terms/ild/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/proton-therapy/> .